WallStreetZenWallStreetZen

NASDAQ: FULC
Fulcrum Therapeutics Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

FULC past revenue growth

How has FULC's revenue growth performed historically?
Company
-55.77%
Industry
143.99%
Market
17.8%
FULC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
FULC's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance

FULC earnings and revenue history

Current Revenue
$2.8M
Current Earnings
-$97.3M
Current Profit Margin
-3,470.1%

FULC Return on Equity

Current Company
-36.6%
Current Industry
-63.5%
Current Market
188%
FULC's Return on Equity (-36.6%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when FULC announces earnings.

FULC Return on Assets

Current Company
-33.6%
Current Industry
2.9%
FULC is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

FULC Return on Capital Employed

Current Company
-39.89%
Current Industry
19.5%
FULC has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

FULC vs Biotech Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
FULC$2.81M-$95.16M-$97.34M-88.03%N/A
VYGR$250.01M$126.46M$132.33M+101.01%+128.28%
TSHA$15.45M-$104.02M-$111.57M+517.55%N/A
TVTX$145.24M-$61.31M-$111.40M-2.43%N/A
PEPG$0.00-$77.37M-$78.63MN/AN/A
View Top Biotech Stocks

FULC earnings dates

Next earnings date
Jun 17, 2024

Fulcrum Therapeutics Earnings & Revenue FAQ

What were FULC's earnings last quarter?

On Invalid Date, Fulcrum Therapeutics (NASDAQ: FULC) reported Q4 2023 earnings per share (EPS) of -$0.40, up 14.89% year over year. Total Fulcrum Therapeutics earnings for the quarter were -$24.76 million. In the same quarter last year, Fulcrum Therapeutics's earnings per share (EPS) was -$0.47.

If you're new to stock investing, here's how to buy Fulcrum Therapeutics stock.

What was FULC's earnings growth in the past year?

As of Q2 2024, Fulcrum Therapeutics's earnings has grown year over year. Fulcrum Therapeutics's earnings in the past year totalled -$97.34 million.

What is FULC's earnings date?

Fulcrum Therapeutics's earnings date is Invalid Date. Add FULC to your watchlist to be reminded of FULC's next earnings announcement.

What was FULC's revenue last quarter?

On Invalid Date, Fulcrum Therapeutics (NASDAQ: FULC) reported Q4 2023 revenue of $871.00 thousand up 27.15% year over year. In the same quarter last year, Fulcrum Therapeutics's revenue was $685.00 thousand.

What was FULC's revenue growth in the past year?

As of Q2 2024, Fulcrum Therapeutics's revenue has grown -55.77% year over year. This is 199.76 percentage points lower than the US Biotechnology industry revenue growth rate of 143.99%. Fulcrum Therapeutics's revenue in the past year totalled $2.81 million.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.